Research ExplorerPublicationsThe neurofilament heavy chain (NfHSMI35) in the cerebrospina...

The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease

Standard

The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease. / Brettschneider, Johannes; Petzold, Axel; Schöttle, Daniel; Claus, Annett; Riepe, Matthias; Tumani, Hayrettin.

In: Dementia and Geriatric Cognitive Disorders, Vol. 21, No. 5-6, 05.2006, p. 291-295.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brettschneider, J, Petzold, A, Schöttle, D, Claus, A, Riepe, M & Tumani, H 2006, 'The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease', Dementia and Geriatric Cognitive Disorders, vol. 21, no. 5-6, pp. 291-295. https://doi.org/10.1159/000091436

APA

Brettschneider, J., Petzold, A., Schöttle, D., Claus, A., Riepe, M., & Tumani, H. (2006). The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 21(5-6), 291-295. https://doi.org/10.1159/000091436

Vancouver

Brettschneider J, Petzold A, Schöttle D, Claus A, Riepe M, Tumani H. The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 2006 May;21(5-6):291-295. https://doi.org/10.1159/000091436

Bibtex

@article{42359b71eb69424e89894694f0e31706,
title = "The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease",
abstract = "Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer's disease (AD), the neurofilament heavy chain isoform, NfHSMI35 was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1-42 (Aβ42), the ratio of amyloid beta fragments Aβ42/Aβ40 (Aβ ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58). Results: CSF NfHSMI35 was elevated in AD and VD as compared to controls (p < 0.05). Total tau was higher in AD as compared to controls (p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD (p < 0.05 each). CSF Aβ42 and Aβ ratios in AD were lower than in MCI and controls (p < 0.05 each). Conclusion: The diagnostic potential of NfHSMI35 is not superior to that of other CSF markers.",
keywords = "Alzheimer's disease, Cerebrospinal fluid, Markers, diagnostic, NfH",
author = "Johannes Brettschneider and Axel Petzold and Daniel Sch{\"o}ttle and Annett Claus and Matthias Riepe and Hayrettin Tumani",
note = "Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2006",
month = may,
doi = "10.1159/000091436",
language = "English",
volume = "21",
pages = "291--295",
journal = "DEMENT GERIATR COGN",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "5-6",

}

RIS

TY - JOUR

T1 - The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease

AU - Brettschneider, Johannes

AU - Petzold, Axel

AU - Schöttle, Daniel

AU - Claus, Annett

AU - Riepe, Matthias

AU - Tumani, Hayrettin

N1 - Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2006/5

Y1 - 2006/5

N2 - Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer's disease (AD), the neurofilament heavy chain isoform, NfHSMI35 was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1-42 (Aβ42), the ratio of amyloid beta fragments Aβ42/Aβ40 (Aβ ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58). Results: CSF NfHSMI35 was elevated in AD and VD as compared to controls (p < 0.05). Total tau was higher in AD as compared to controls (p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD (p < 0.05 each). CSF Aβ42 and Aβ ratios in AD were lower than in MCI and controls (p < 0.05 each). Conclusion: The diagnostic potential of NfHSMI35 is not superior to that of other CSF markers.

AB - Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer's disease (AD), the neurofilament heavy chain isoform, NfHSMI35 was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1-42 (Aβ42), the ratio of amyloid beta fragments Aβ42/Aβ40 (Aβ ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58). Results: CSF NfHSMI35 was elevated in AD and VD as compared to controls (p < 0.05). Total tau was higher in AD as compared to controls (p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD (p < 0.05 each). CSF Aβ42 and Aβ ratios in AD were lower than in MCI and controls (p < 0.05 each). Conclusion: The diagnostic potential of NfHSMI35 is not superior to that of other CSF markers.

KW - Alzheimer's disease

KW - Cerebrospinal fluid

KW - Markers, diagnostic

KW - NfH

UR - http://www.scopus.com/inward/record.url?scp=33646707066&partnerID=8YFLogxK

U2 - 10.1159/000091436

DO - 10.1159/000091436

M3 - SCORING: Journal article

C2 - 16484807

AN - SCOPUS:33646707066

VL - 21

SP - 291

EP - 295

JO - DEMENT GERIATR COGN

JF - DEMENT GERIATR COGN

SN - 1420-8008

IS - 5-6

ER -